Tri atresia; Valve disorder - tricuspid atresia; Congenital heart - tricuspid atresia; Cyanotic heart disease - tricuspid atresia
Tricuspid atresia is a type of heart disease that is present at birth (
Tricuspid atresia is an uncommon form of congenital heart disease. It affects about 5 in every 100,000 live births. One in 5 people with this condition will also have other heart problems.
Normally, blood flows from the body into the right atrium, then through the tricuspid valve to the right ventricle and on to the lungs. If the tricuspid valve does not open, the blood cannot flow from the right atrium to the right ventricle. Because of the problem with the tricuspid valve, blood ultimately cannot enter the lungs. This is where it must go to pick up oxygen (becomes oxygenated).
Instead, the blood passes through a hole between the right and left atrium. In the left atrium, it mixes with oxygenated blood returning from the lungs. This mix of oxygenated and de-oxygenated blood is then pumped out into the body. This causes oxygen level in the blood to be lower than normal.
The lungs receive blood either through a hole between the right and left ventricles, or through a fetal vessel called the ductus arteriosus that connects the pulmonary artery (artery to the lungs) to the aorta (main artery to the body). The ductus arteriosus is present when a baby is born, but closes by itself shortly after birth.
This condition may be discovered during routine prenatal ultrasound imaging or when the baby is examined after birth. Bluish skin is present at birth. A heart murmur is often present at birth and may increase in loudness over several months.
Tests may include the following:
Once the diagnosis is made, the baby will often be admitted to the neonatal intensive care unit (NICU). A medicine called prostaglandin E1 may be used to keep the ductus arteriosis open so that blood can circulate to the lungs.
The condition always requires surgery. If the heart is unable to pump enough blood out to the lungs and rest of the body, the first surgery most often takes place within the first few days of life. In this procedure, an artificial shunt is inserted to keep blood flowing to the lungs. In some cases, this first surgery is not needed.
Afterward, the baby goes home in most cases. The child will need to take one or more daily medicines and be closely followed by a pediatric cardiologist. This doctor will decide when the second stage of surgery should be done.
The next stage of surgery is called the Glenn shunt or hemi-Fontan procedure. This procedure connects half of the veins carrying blue blood from the upper half of the body directly to the pulmonary artery. The surgery is most often done when the child is between 4 to 6 months old.
During stage I and II, the child may still look blue (cyanotic).
Stage III, the final step, is called the Fontan procedure. The rest of the veins carrying blue blood from the body are connected directly to the pulmonary artery leading to the lungs. The left ventricle now only has to pump to the body, not the lungs. This surgery is usually performed when the child is 18 months to 3 years old. After this final step, the baby is no longer blue.
In most cases, surgery will improve the condition.
Complications may include:
Contact your health care provider right away if your infant has:
There is no known way to prevent tricuspid atresia.
Fraser CD, Carberry KE. Congenital heart disease. In: Townsend CM Jr, Beauchamp RD, Evers BM, Mattox KL, eds. Sabiston Textbook of Surgery. 19th ed. Philadelphia, PA: Elsevier Saunders; 2012:chap 59.
Webb GD, Smallhorn JF, Therrien J, Redington AN. Congenital heart disease. In: Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 10th ed. Philadelphia, PA: Elsevier Saunders; 2015:chap 62.
Last reviewed on: 10/22/2015
Reviewed by: Larry A. Weinrauch, MD, Assistant Professor of Medicine, Harvard Medical School, Cardiovascular Disease and Clinical Outcomes Research, Watertown, MA. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Isla Ogilvie, PhD, and the A.D.A.M. Editorial team.